Loading stock data…
Corcept Therapeutics Incorporated (CORT)
$87.89+0.57 (+0.65%)
After Hours$86.99-0.90 (-1.02%)· Last close Jun 29
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Corcept Therapeutics Incorporated in the Healthcare sector is trading at $87.89 with a market capitalization of $8.9B. Wall Street consensus targets $88.00 (5 analysts), implying a +0.1% move over the next 12 months. The stock is currently near its 52-week high of $91.00, remaining 45.7% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $164.90M↓ | $202.13M↓ | $207.64M↑ | $194.43M↑ | $157.21M |
| Gross Profit | $162.02M↓ | $199.58M↓ | $203.04M↑ | $191.00M↑ | $154.81M |
| Operating Income | -$49.60M↓ | $4.49M↓ | $10.22M↓ | $26.68M↑ | $3.42M |
| Net Income | -$31.76M↓ | $24.29M↑ | $19.67M↓ | $35.15M↑ | $20.55M |
Peer Comparison
JNJUNHPFE
Fundamentals
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.92B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
7.42%
Volume
Today's trading volume
820,891
Recent News
3 Unpopular Stocks We Steer Clear Of
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
Corcept Resubmits NDA for Relacorilant in Cushing's Syndrome
CORT resubmits relacorilant NDA for Cushing's syndrome, with updated analyses and data from multiple clinical studies supporting the filing.
June 2026's Leading Growth Stocks With Strong Insider Ownership
In the last week, the United States market has stayed flat, yet it has seen a significant rise of 24% over the past year with earnings forecasted to grow by 19% annually. In this environment, growth companies with high insider ownership can be particularly appealing as they often suggest confidence in a company's future prospects and alignment of interests between management and shareholders.
Esquire Financial Holdings And 2 Insider Picks For Growth Potential
Over the last 7 days, the United States market has remained flat, yet it has seen a significant increase of 24% over the past year with earnings forecasted to grow by 19% annually. In this environment, stocks with high insider ownership can signal confidence from those closest to the company and may present intriguing opportunities for growth potential.
Spotlight On June 2026's Insider-Favored Growth Stocks
Over the last 7 days, the United States market has experienced a 2.4% drop, yet it has shown resilience with a 22% rise over the past year and anticipated earnings growth of 18% per annum in the coming years. In this environment, companies that exhibit strong growth potential coupled with high insider ownership may offer unique insights into their future prospects as insiders typically have a vested interest in their success.